LEADIANT BIOSCI INC
Big PharmaLEADIANT BIOSCI INC is a major pharmaceutical company focused on Ophthalmology. Key products include CYSTARAN.
LEADIANT BIOSCI INC's Key Drugs
LEADIANT BIOSCI INC's core commercial portfolio centers on CYSTARAN, spanning Ophthalmology — its most strategically important drugs approved in the last 15 years.
LEADIANT BIOSCI INC's Recent FDA Approvals
New NDA/BLA approvals for LEADIANT BIOSCI INC over the last two years — novel drugs only, excluding generics and label supplements.
LEADIANT BIOSCI INC's Therapeutic Areas
LEADIANT BIOSCI INC's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LEADIANT BIOSCI INC's Top Competitors
LEADIANT BIOSCI INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LEADIANT BIOSCI INC Pipeline Snapshot
Active clinical trials for LEADIANT BIOSCI INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CYSTARAN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/2 completed
- • Speed: 58 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1969-07-22
- Latest
- 2022-02-25
- Applications
- 8
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges